Akili’s new era as a subsidiary of Virtual Therapeutics will start with FDA approval of its digital therapeutic for attention-deficit hyperactivity disorder (ADHD) in adults, a key part of
Two executives at a telehealth start-up have been arrested and are facing allegations of fraud involving the distribution of medicines for attention-deficit hyperactivity disorder (ADHD).
In another deal that highlights the pressures facing companies in the digital health sector, Akili Interactive has agreed to go private in a merger with Virtual Therapeuti
Digital health company Akili is on the brink of its first major expansion beyond the US, partnering with Shionogi to file a localised version of its attention deficit hype
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh